牛牛AI助理已提取核心訊息
Seelos Therapeutics, Inc., a biopharmaceutical company, has filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on March 6, 2024. The filing is to register an additional 106,206 shares of its common stock under the company's Amended and Restated 2012 Stock Long Term Incentive Plan. This plan, which includes shares issuable pursuant to options granted, has already received approval from Seelos Therapeutics' stockholders. The newly registered shares add to the previously registered 680,429 shares under the same plan, as detailed in prior registration statements. The company's Annual Report for the fiscal year ended December 31, 2023, and Current Reports filed on January 10 and January 22, 2024, are incorporated by reference into this registration statement. Seelos Therapeutics, based in New York, is incorporated in Nevada and has provided contact information for investors to request copies of the referenced filings without charge.
Seelos Therapeutics, Inc., a biopharmaceutical company, has filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on March 6, 2024. The filing is to register an additional 106,206 shares of its common stock under the company's Amended and Restated 2012 Stock Long Term Incentive Plan. This plan, which includes shares issuable pursuant to options granted, has already received approval from Seelos Therapeutics' stockholders. The newly registered shares add to the previously registered 680,429 shares under the same plan, as detailed in prior registration statements. The company's Annual Report for the fiscal year ended December 31, 2023, and Current Reports filed on January 10 and January 22, 2024, are incorporated by reference into this registration statement. Seelos Therapeutics, based in New York, is incorporated in Nevada and has provided contact information for investors to request copies of the referenced filings without charge.
生物製藥公司Seelos Therapeutics, Inc. 已於2024年3月6日向美國證券交易委員會（SEC）提交了S-8表格註冊聲明。該文件旨在根據該公司經修訂和重述的2012年股票長期激勵計劃再註冊106,206股普通股。該計劃包括根據授予的期權發行的股票，已獲得Seelos Therapeutics股東的批准。如先前的註冊聲明所述，新註冊的股票增加了先前在同一計劃下注冊的680,429股股份。公司截至2023年12月31日的財政年度的年度報告以及於2024年1月10日和1月22日提交的當前報告以引用方式納入本註冊聲明。總部位於紐約的Seelos Therapeutics在內華達州註冊成立，並已提供聯繫信息，供投資者免費索取參考文件副本。
生物製藥公司Seelos Therapeutics, Inc. 已於2024年3月6日向美國證券交易委員會（SEC）提交了S-8表格註冊聲明。該文件旨在根據該公司經修訂和重述的2012年股票長期激勵計劃再註冊106,206股普通股。該計劃包括根據授予的期權發行的股票，已獲得Seelos Therapeutics股東的批准。如先前的註冊聲明所述，新註冊的股票增加了先前在同一計劃下注冊的680,429股股份。公司截至2023年12月31日的財政年度的年度報告以及於2024年1月10日和1月22日提交的當前報告以引用方式納入本註冊聲明。總部位於紐約的Seelos Therapeutics在內華達州註冊成立，並已提供聯繫信息，供投資者免費索取參考文件副本。
有用
沒用